Callan JMB partners in a collaboration for JKB-122, ensuring manufacturing compliance and operational readiness for healthcare logistics.
Quiver AI Summary
Callan JMB Inc. has announced its role as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Biostax Corp (Attune) and SGP Holdings, to support the U.S.-based manufacturing and development of the immune restoration platform JKB-122 (Lodonal™). Callan JMB will provide independent validation of manufacturing, quality systems, and supply chain operations to ensure compliance and readiness as the program moves toward Phase 2b/3 clinical development and large-scale manufacturing. The collaboration emphasizes the importance of federal standards and operational integrity in healthcare logistics, particularly for regulated programs. The partnership aims to advance multiple therapeutic indications, leveraging Callan JMB's expertise in logistics, compliance, and operational infrastructure.
Potential Positives
- Callan JMB is positioned as an independent oversight partner, reinforcing its credibility and expertise in regulated manufacturing and supply chain integrity within the healthcare industry and emergency management sectors.
- The collaboration emphasizes U.S.-based technology transfer and manufacturing, potentially elevating Callan JMB’s role in supporting federal programs and large-scale deployments.
- Callan JMB's involvement ensures compliance with federal standards, enhancing its reputation as a reliable partner for regulated healthcare and government programs.
- The announcement supports Callan JMB's expanding capabilities in operational infrastructure, aligning with industry trends towards platform-based therapeutic development.
Potential Negatives
- Callan JMB's reliance on third-party collaborations may raise concerns about its control over the quality and integrity of the processes involved in the JKB-122 (Lodonal™) immune restoration platform, potentially reflecting inadequacies in its own capabilities.
- The company emphasizes independent oversight and validation, which may imply existing gaps in its quality systems and supply chain operations that necessitate external verification.
- The mention of significant industry risks and uncertainties related to regulatory approvals and clinical development outcomes may highlight potential vulnerabilities in Callan JMB's future growth prospects.
FAQ
What is Callan JMB's role in the upcoming JKB-122 clinical development?
Callan JMB acts as an independent infrastructure and oversight partner ensuring compliance and readiness for manufacturing and supply chain operations.
How does Callan JMB ensure supply chain integrity?
Callan JMB provides independent validation across manufacturing and quality systems to ensure consistency and compliance in operations.
What is the primary focus of the JKB-122 (Lodonal™) program?
The program aims at immune restoration and recovery in patients suffering from post-infectious illnesses, with a focus on multiple indications.
Who are the collaborators involved in the JKB-122 initiative?
Key collaborators include DifGen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp (Attune Biotech), and SGP Holdings.
What technologies support the JKB-122 program development?
The program uses a platform-based approach incorporating shared manufacturing, formulation development, and regulatory infrastructure for scalability.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CJMB Insider Trading Activity
$CJMB insiders have traded $CJMB stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CJMB stock by insiders over the last 6 months:
- WAYNE D WILLIAMS (CEO, Chairman and President) has made 6 purchases buying 65,343 shares for an estimated $109,257 and 0 sales.
- DAVID J CROYLE (Chief Medical Officer) has made 2 purchases buying 25,000 shares for an estimated $43,927 and 0 sales.
- GERALD DIAL has made 2 purchases buying 2,000 shares for an estimated $2,409 and 0 sales.
- LIBERTY SMITH DUKE has made 2 purchases buying 1,512 shares for an estimated $2,334 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CJMB Hedge Fund Activity
We have seen 7 institutional investors add shares of $CJMB stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CABLE CAR CAPITAL, LP removed 392,586 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $435,770
- BARD ASSOCIATES INC removed 114,989 shares (-29.1%) from their portfolio in Q4 2025, for an estimated $127,637
- CITADEL ADVISORS LLC added 44,002 shares (+inf%) to their portfolio in Q4 2025, for an estimated $48,842
- CREATIVE PLANNING added 35,685 shares (+21.0%) to their portfolio in Q4 2025, for an estimated $39,610
- UBS GROUP AG removed 27,390 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $30,402
- RENAISSANCE TECHNOLOGIES LLC added 11,400 shares (+inf%) to their portfolio in Q4 2025, for an estimated $12,654
- DRW SECURITIES, LLC added 10,296 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,428
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Independent oversight reinforces manufacturing, supply chain integrity, and federal readiness for a platform designed to scale across multiple indications
SPRING BRANCH, Texas, March 27, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics and operational infrastructure company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its role as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Biostax Corp (“Biostax”), doing business as Attune Biotech (“Attune”), and SGP Holdings. The collaboration supports U.S.-based technology transfer, formulation development, and manufacturing scale-up for the JKB-122 (Lodonal ™ ) immune restoration platform.
Callan JMB’s role focuses on independent validation across manufacturing, quality systems, and supply chain operations—helping ensure consistency, compliance, and readiness as the program advances toward Phase 2b/3 clinical development and potential large-scale manufacturing and deployment. This includes alignment with federal standards associated with agencies such as the Biomedical Advanced Research and Development Authority (BARDA), the U.S. Department of Defense, and the U.S. Department of Veterans Affairs. This support may also include packaging, serialization, and product traceability coordination to support regulatory compliance and potential federal deployment requirements.
Independent third-party oversight helps ensure compliance, documentation, and operational integrity across clinical, government, and commercial healthcare programs, particularly those involving regulated manufacturing, controlled storage, product traceability, and coordinated distribution infrastructure.
The work builds on Callan JMB’s previously announced agreement supporting Attune’s multi-asset therapeutic pipeline and reflects the Company’s expanding role supporting regulated healthcare programs that require compliant logistics, manufacturing oversight, and operational infrastructure capable of supporting clinical development, commercialization, and government program deployment.
Wayne Williams, President and Chief Executive Officer of Callan JMB, stated: “Callan JMB has deep experience supporting complex, regulated programs where execution, compliance, and visibility are critical. Our role is to provide independent infrastructure and oversight across manufacturing, storage, monitoring, packaging, and distribution—helping ensure these programs are built to scale and ready for real-world clinical, commercial, and government deployment.”
Biostax is advancing programs in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), Autoimmune Hepatitis (AIH), Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), and Metabolic Dysfunction–Associated Steatohepatitis (MASH), with additional programs planned in HIV immune non-responders, HIV virologically failing therapy, and chronic pain associated with immune dysfunction. These programs are supported by a shared CMC, pharmacology, and safety framework designed to enable development across multiple indications using a platform-based approach.
Noreen Griffin, Chief Executive Officer of Biostax Corp d/b/a Attune Biotech, said: “This marks an important step in advancing our program into a platform model. Establishing U.S.-based manufacturing and a unified CMC framework creates the foundation for multi-indication development and future commercialization. Callan JMB was selected for its ability to provide independent oversight across manufacturing and supply chain systems—helping ensure the level of rigor, compliance, and readiness required for federal programs and large-scale deployment.”
The lead PASC program for JKB-122 (Lodonal ™ ) has received FDA authorization to proceed under an active Investigational New Drug application, with a Phase 2b/3 clinical study designed to evaluate immune restoration and functional recovery in post-infectious illness. The platform strategy includes development across multiple indications supported by shared manufacturing and regulatory infrastructure.
DifGen Pharmaceuticals and Aveva Drug Delivery Systems are leading formulation development and manufacturing expansion across multiple dose strengths, titration and maintenance regimens, sustained-release formulations, pediatric programs, and stability optimization, supported by U.S.-based GMP manufacturing scale-up.
Ramandeep Singh Jaj and Santhanakrishnan Srinivasan, Founders and Co-CEOs of DifGen Pharmaceuticals, stated: “We are very excited to be part of this collaboration and to support the advancement of what we believe is a highly innovative upstream immune restoration platform. This program is unique in that it is built around a platform formulation and manufacturing strategy across multiple dose strengths and multiple indications. As the platform expands into additional indications, we look forward to supporting not only manufacturing and formulation development, but also a broader role in supporting future clinical development programs built on this platform.”
The collaboration reflects broader industry momentum toward platform-based therapeutic development and integrated manufacturing strategies designed to support multiple indications, scalable manufacturing, and coordinated distribution infrastructure.
About Callan JMB Inc.
Callan JMB Inc. (NASDAQ: CJMB) is a vertically integrated logistics and operational infrastructure company empowering the healthcare industry and emergency management agencies through fulfillment, storage, environmental monitoring, cold chain logistics, packaging, serialization, and supply chain coordination services. The Company supports regulated healthcare programs requiring compliant logistics, controlled environments, product traceability, and operational infrastructure for clinical development, commercial distribution, and government program deployment. Callan JMB’s expertise spans supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness, providing secure and reliable infrastructure for critical healthcare programs.
About Biostax Corp d/b/a Attune Biotech Inc.
Biostax Corp d/b/a Attune Biotech Inc. (“Attune”) is a clinical-stage biotechnology company with a diversified pipeline of therapeutic assets and fully U.S.-based cGMP manufacturing capability. The company's lead program, Lodonal ™ (JKB-122), is an immune restoration therapeutic platform designed to restore immune homeostasis and is being developed across multiple clinical indications. The company leverages 505(b)(2) regulatory strategies, platform manufacturing, and strategic public-private partnerships to advance capital-efficient drug development and scalable therapeutic platforms.
About DifGen Pharmaceuticals / Aveva Drug Delivery Systems
DifGen Pharmaceuticals and Aveva Drug Delivery Systems are U.S.-based pharmaceutical development and manufacturing organizations specializing in formulation development, drug delivery technologies, and GMP manufacturing scale-up. The organizations support platform-based drug development programs across multiple dosage forms, strengths, and release profiles, supporting clinical development and commercial manufacturing.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the development, manufacturing, scale-up, and potential deployment of JKB-122 (Lodonal ™ ), and Callan JMB’s role in supporting manufacturing oversight, logistics infrastructure, and regulated healthcare and government programs. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these statements. These risks and uncertainties include, but are not limited to, regulatory approvals, clinical development outcomes, manufacturing scale-up, government program participation, and other factors described in Callan JMB’s filings with the U.S. Securities and Exchange Commission. Callan JMB undertakes no obligation to update any forward-looking statements except as required by law.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
[email protected]
212.896.1254
